Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.77 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.74 |
| ▸ | INSR | P06213 | 1/20 | 0.74 |
| ▸ | INSRR | P14616 | 1/20 | 0.74 |
| ▸ | LTK | P29376 | 1/20 | 0.74 |
| ▸ | CLK1 | P49759 | 1/20 | 0.74 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.74 |
| ▸ | MERTK | Q12866 | 1/20 | 0.74 |
| ▸ | DAPK2 | Q9UIK4 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168312 | 0.92 | ALK (0.73) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL17048167 | 0.91 | ALK (0.68) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL17048407 | 0.91 | ALK (0.67) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL17048379 | 0.88 | ALK (0.75) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL20182921 | 0.88 | ALK (0.86) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL17048202 | 0.87 | ALK (1.00) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL21473707 | 0.86 | ALK (0.85) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL17048359 | 0.86 | ALK (1.00) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL17048283 | 0.86 | ALK (1.00) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL21458984 | 0.86 | ALK (1.00) | ALKDAPK3INSRINSRRLTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781208-B2 | 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781208-B2 | 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3110815-B1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEV INC (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-20190315741-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315741-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-17 | — | — | US | disclosed |
| EP-3541816-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | The Regents of The University of Michigan (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018094134-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018094134-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-05-24 | — | — | WO | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3110815-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | Jiangsu Ascentage Biomed Development Inc. (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | ALK, BCL6, BCL6B | ALK 1/4885DAPK3 215/4885INSR 724/4885 |
| US-20190315741-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | ALK, KRAS, ABL1 | ALK 1/4885DAPK3 2151/4885INSR 39/4885 |
| US-10781208-B2 | 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors | ALK, KRAS, ABL1 | ALK 1/4885DAPK3 2244/4885INSR 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.